v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
COSTS AND EXPENSES:        
Research and development $ 1,995,571 $ 2,333,058 $ 5,798,526 $ 6,365,868
General and administrative 1,091,921 1,150,710 3,647,412 3,146,605
Total costs and expenses 3,087,492 3,483,768 9,445,938 9,512,473
LOSS FROM OPERATIONS (3,087,492) (3,483,768) (9,445,938) (9,512,473)
OTHER INCOME:        
Gain on revaluation of derivative warrants 66,000 9,100 19,050 16,625
Interest income, net 6,558 3,969 15,440 12,297
Total other income, net 72,558 13,069 34,490 28,922
NET LOSS (3,014,934) (3,470,699) (9,411,448) (9,483,551)
DEEMED DIVIDEND ON PREFERRED STOCK (2,241,795) 0 (2,241,795) 0
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (5,256,729) $ (3,470,699) $ (11,653,243) $ (9,483,551)
BASIC AND DILUTED NET LOSS PER COMMON SHARE $ (1.65) $ (2.58) $ (5.29) $ (7.30)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE 3,184,856 1,347,097 2,204,554 1,298,643

Source